Tag: COPD
CHEST: Dupilumab for COPD Tied to Improvement in Health-Related Quality of Life
Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
Approval is the first in the U.S. for a biologic for the condition
Preclinical Blood Test IDs Risk for Respiratory Death, Incident COPD
Signature of respiratory susceptibility can identify individuals at risk for COPD, hospitalization from respiratory exacerbation, and death
People With Chronic Liver Disease Face More Barriers to Health Care
Findings tied to higher prevalence of socioeconomic vulnerabilities compared with those with chronic obstructive pulmonary disease or cardiovascular disease
Two-Thirds of COPD Hospitalized Patients Misuse Inhalers
Most misuse inhalers due to critical error in the inhalation technique
Race-Neutral Metrics More Accurately Predict Risk in COPD
GLI-Global differentiated all-cause mortality risk between normal spirometry and first grade of COPD in adjusted analyses
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
Those receiving pulmonologist-directed treatment have less subsequent health care utilization for respiratory illness
Dupilumab Tied to Fewer Exacerbations in COPD With Type 2 Inflammation
Increase seen in prebronchodilator forced expiratory volume in one second with dupilumab versus placebo at weeks 12, 52
Bisoprolol Does Not Reduce Exacerbations in At-Risk COPD Patients
No reduction seen in number of self-reported exacerbations treated with oral corticosteroids, antibiotics, or both
Female Reproductive Factors Linked to Risk for COPD
Age at menarche, number of children, number of miscarriages and stillbirths, age at natural menopause linked to COPD
